4//SEC Filing
INTERCEPT PHARMACEUTICALS INC 4
Accession 0001144204-15-041689
CIK 0001270073operating
Filed
Jul 7, 8:00 PM ET
Accepted
Jul 8, 9:00 PM ET
Size
22.4 KB
Accession
0001144204-15-041689
Insider Transaction Report
Form 4
Adorini Luciano
Chief Scientific Officer
Transactions
- Sale
Common Stock
2015-07-06$238.64/sh−367$87,580→ 13,809 total - Sale
Common Stock
2015-07-06$241.57/sh−1,000$241,571→ 11,609 total - Exercise/Conversion
Common Stock
2015-07-06$21.50/sh+4,000$86,000→ 14,776 total - Exercise/Conversion
Option to Purchase Common Stock
2015-07-06−67→ 0 totalExercise: $8.67Exp: 2021-10-13→ Common Stock (67 underlying) - Sale
Common Stock
2015-07-06$2538.02/sh−600$1,522,815→ 14,176 total - Sale
Common Stock
2015-07-06$241.81/sh−770$186,194→ 10,839 total - Sale
Common Stock
2015-07-06$240.63/sh−1,200$288,752→ 12,609 total - Exercise/Conversion
Option to Purchase Common Stock
2015-07-06−4,000→ 2,923 totalExercise: $21.50Exp: 2022-11-16→ Common Stock (4,000 underlying) - Exercise/Conversion
Common Stock
2015-07-06$8.67/sh+67$581→ 10,776 total - Sale
Common Stock
2015-07-06$243.69/sh−130$31,680→ 10,709 total
Footnotes (8)
- [F1]The reported transaction was made pursuant to a 10(b)5-1 plan adopted by the reporting person on March 9, 2015.
- [F2]All the shares underlying this option have fully vested.
- [F3]The remaining shares underlying this option vest on a pro rata monthly basis through January 1, 2016, subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan.
- [F4]This transaction was executed in multiple trades at prices ranging from $237.52 to $238.50. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F5]This transaction was executed in multiple trades at prices ranging from $238.55 to $238.87. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F6]This transaction was executed in multiple trades at prices ranging from $240.00 to $240.99. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F7]This transaction was executed in multiple trades at prices ranging from $241.0150 to $242.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F8]This transaction was executed in multiple trades at prices ranging from $242.3200 to $242.9600. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Documents
Issuer
INTERCEPT PHARMACEUTICALS INC
CIK 0001270073
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001270073
Filing Metadata
- Form type
- 4
- Filed
- Jul 7, 8:00 PM ET
- Accepted
- Jul 8, 9:00 PM ET
- Size
- 22.4 KB